The discovery sequence ran in this order: first the drugs (opium, morphine, heroin), then the receptors (mu, kappa, delta), and only then the realization that the brain was making its own ligands for those receptors. Morphine did not invent the system. Morphine borrowed it.
The brain's endogenous opioids are three families of peptides: endorphins, enkephalins, dynorphins. They act at the same receptors as morphine, fentanyl, and heroin — chiefly the mu-opioid receptor for analgesia and reward, with kappa and delta playing more nuanced roles in mood and stress.
Their job in the unperturbed brain is to dampen pain and to produce the quiet sense of ease that follows effort. The runner's settled feeling after a long run, the calm of a mother holding her newborn, the body's own response to acute injury that lets the soldier walk off a wound and only feel it later — these are endogenous opioid moments. The system was never designed to be hit by an exogenous full agonist a hundred times a day.
When an exogenous opioid arrives — morphine after surgery, oxycodone for chronic pain, fentanyl on the street — it occupies the same receptors and produces the same effects, but at a magnitude and duration the system was not built for. Chronic activation downregulates the receptors and the endogenous peptides. The patient now needs the drug to feel normal. Without it, they feel pain, dysphoria, autonomic withdrawal. This is the substrate of opioid use disorder.
Three drugs at the same receptor system illustrate the spectrum.
Methadone is a full mu agonist with a long half-life. Given once daily at a stable dose, it occupies the receptors steadily — no peaks, no troughs — and the craving and withdrawal stop. It saves lives in opioid use disorder. It also carries overdose risk, because as a full agonist it has no ceiling.
Buprenorphine is a partial mu agonist. It occupies the receptor and produces a submaximal effect — enough to prevent withdrawal and craving, not enough to produce the euphoric surge that drives addiction. It also has a ceiling effect, which is why buprenorphine overdose is dramatically less common than methadone overdose. The film placed under the tongue is one of the most consequential additions to outpatient psychiatry of the last generation.
Naltrexone is a full antagonist. It occupies the receptor and produces no effect. If the patient uses an opioid while on naltrexone, the opioid simply cannot bind. It is useful in motivated patients but cannot be started while the patient is physiologically dependent — initiating naltrexone in a dependent patient precipitates immediate withdrawal.
Hold the framework: full agonist, partial agonist, antagonist. The same receptor, three molecular relationships, three clinical roles.